source
- Novartis shares tumble after late-stage failure of Avidity-acquired drugNovartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…
- Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomesNovartis said its late-stage Phase 3 trial of the antisense drug pelacarsen did not show a benefit in reducing major cardiovascular events compared with placebo. The result adds to a recent string…